SEATTLE--(BUSINESS WIRE)--Reverba, a leading global patient engagement company, today announced the launch of reverbaBRIDGE™, a comprehensive digital platform that powers patient engagement solutions for clinical teams in the biopharmaceutical industry. ReverbaBRIDGE enables data- and technology-driven solutions to address the most challenging elements of patient engagement for successful clinical trials, from recruiting and informing the right patients to building lasting relationships during and beyond clinical development.
“Drug developers face unprecedented challenges and barriers to reach and succeed in the clinic, and at the same time, they have never been more interested in making the patient experience a central focus of the process,” said Cheryl Lubbert, CEO and co-founder of Reverba. “With a foundation of 20 years of experience building authentic and impactful relationships with patients, we empower biopharmaceutical companies to connect with their consumers as they advance their products throughout the product lifecycle. We are excited to have Addison Freeman take on the role of SVP, Clinical Operations where he’ll helm our clinical division to provide solutions for R&D patient engagement.”
Freeman comes to Reverba from a strategy consulting and analytics background with companies such as Precision Xtract. He previously worked at Reverba as Vice President of Strategy and Innovation, where he helped develop many of the clinical strategies that have evolved into the clinical trial solutions he manages today.
“Clinical trial design, enrollment, retention and diversity continue to challenge the biopharmaceutical industry. We’ve seen continued problems in trial retention, with a nearly 25% decrease in retention rates between 2015 and 2019 compounding an already problematic issue. There is a big drive to meet enrollment targets, but success in recruitment hasn’t translated to an improved pre-trial, in-trial, or post-trial patient experience, to date. We believe improving the patient experience is a major component of addressing the retention issue plaguing pharmaceutical R&D,” said Freeman.
Reverba’s clinical division provides the pathway for significant improvement in the patient experience using reverbaBRIDGE, a proprietary built-for-purpose solution that is globally enabled, uniquely customizable and always compliant.
With Reverba’s recent evolution from the Health Perspectives Group, the new clinical team Freeman heads is innovating how biopharmaceutical companies can compliantly connect with patients to improve recruitment and retention by applying the commercial principles of patient engagement to the clinical trial setting.
About reverbaBRIDGE
Reverba’s comprehensive clinical offering allows biopharmaceutical companies to gain actionable insights to improve the clinical trial experience to optimize recruitment and increase retention. With 20 years of strategic patient engagement experience, Reverba is uniquely positioned to bridge the gap between clinical client sponsors, trial sites, and the patients they serve.
The reverbaBRIDGE platform supports a scalable high-touch experience for trial prequalification, globally enabled patient and investigator in-trial experience surveys, and compliant sponsor-to-participant communication, both during and after trials to develop and maintain sponsor-to-participant relationships.
About Reverba:
Reverba is a global patient engagement company that creates transformative tech-enabled solutions to build a bridge between patients and biopharma companies, from clinical development through commercialization. Through its Clinical and Commercial divisions, Reverba creates comprehensive custom patient engagement solutions using its proprietary reverbaBRIDGE™ technology platform and reverbaCONNECT™ foundational services. Reverba infuses compliance throughout all of its technology platforms and patient engagement solutions, maintaining SOC2 including ISAE 3000 certification for the highest level of security. For more information, visit www.reverba.com or contact connect@reverba.com
